TORONTO, June 20, 2019 /CNW/ — Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which …
Latest News From Lumira Ventures
Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy
– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …
Bardy Diagnostics™ Selected as Winner of the MedTech Breakthrough Award For Best New Diagnostic Technology
SEATTLE, June 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health …
Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors
Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a Phase 3-stage biopharmaceutical company developing STS101, …
enGene Appoints José M. Lora, Ph.D. as Chief Scientific Officer
MONTRÉAL and BOSTON, May 29, 2019 — enGene Inc., the high growth biotechnology company developing the Gene Pill™ – a robust, proprietary non-viral vector platform to deliver gene therapies via oral administration – today announced the appointment of José M. Lora, Ph.D., as Chief Scientific …
Bardy Diagnostics™ Selected as Winner of the Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring
SEATTLE, May 7, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced it has been selected as the winner of the North American Remote Cardiac Monitoring Technology Innovation Award by Frost & …
Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing
Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …
BAROnova Announces FDA Approval of the TransPyloric Shuttle® (TPS®) Device
A First-in-Class, Non-Surgical Solution for Obesity Approved for One-Year of Device Treatment, Offering Patients Potentially More Durable Weight Loss and Health Benefits SAN CARLOS, Calif., April 23, 2019 /PRNewswire/ — BAROnova, Inc., a medical device company focused on the development of first-in-class …
Bardy Diagnostics™ Announces $35.5M in Series B Funding Round
SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion …
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy ANN ARBOR, MICHIGAN // Apr. 8, 2019 – HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed …
Edwards Lifesciences announces exclusive right to acquire Corvia Medical, Inc.
IRVINE, Calif., — Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in …
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 …
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT at Week 4 Primary endpoint of drop discomfort at 1-minute on Day …
Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company (“Lilly”). In accordance with Zymeworks’ 2014 licensing and …
Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a major medical meeting in 2019 NEW ORLEANS, Dec. 03, …